GSK's (GSK) "Underweight" Rating Reaffirmed at JPMorgan Chase & Co.

GSK (LON:GSK - Get Free Report)'s stock had its "underweight" rating reissued by analysts at JPMorgan Chase & Co. in a note issued to investors on Friday, Marketbeat Ratings reports.

A number of other research analysts have also commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a GBX 1,450 ($19.45) price objective on shares of GSK in a research report on Tuesday, July 8th. Shore Capital reaffirmed a "buy" rating on shares of GSK in a research report on Wednesday, April 30th.

GSK Trading Down 4.6%

Shares of LON:GSK traded down GBX 65 ($0.87) during mid-day trading on Friday, hitting GBX 1,348 ($18.08). The stock had a trading volume of 17,188,422 shares, compared to its average volume of 13,779,384. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The company has a market cap of £54.70 billion, a PE ratio of 21.78, a P/E/G ratio of 1.24 and a beta of 0.31. GSK has a 12-month low of GBX 1,242.50 ($16.67) and a 12-month high of GBX 1,678.68 ($22.52). The company's 50 day moving average is GBX 1,435.32 and its 200-day moving average is GBX 1,423.08.

GSK (LON:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, sell-side analysts predict that GSK will post 175.980975 EPS for the current year.

Insiders Place Their Bets

In related news, insider Jonathan Symonds acquired 1,350 shares of the firm's stock in a transaction on Friday, June 20th. The shares were purchased at an average cost of GBX 1,435 ($19.25) per share, for a total transaction of £19,372.50 ($25,985.92). Also, insider Emma Walmsley sold 5,473 shares of the company's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of GBX 1,449 ($19.44), for a total transaction of £79,303.77 ($106,376.62). Over the last three months, insiders have bought 1,905 shares of company stock valued at $2,732,835. 1.61% of the stock is currently owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.